Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

(2012) Dan M. Patterson et al.   CLINICAL CANCER RESEARCH

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

(2010) J D Lickliter et al.   BRITISH JOURNAL OF CANCER

Fit-for-purpose biomarker method validation in anticancer drug development

(2010) Jeffrey Cummings et al.   DRUG DISCOVERY TODAY

Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer

(2010) Luigi De Petris et al.   EUROPEAN JOURNAL OF CANCER

Utilization of cytokeratin-based biomarkers for pharmacodynamic studies

(2010) Stig Linder et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503

(2010) Lori Rice et al.   MICROVASCULAR RESEARCH

Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy

(2009) Jian-Mei Hou et al.   AMERICAN JOURNAL OF PATHOLOGY

Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response

(2009) L C Scott et al.   BRITISH JOURNAL OF CANCER

Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon α: possible use as a surrogate marker

(2009) M B Fisher et al.   CANCER GENE THERAPY

Preclinical evaluation of vascular-disrupting agents in Ewing’s sarcoma family of tumours

(2009) Surita Dalal et al.   EUROPEAN JOURNAL OF CANCER

Cytokeratins 8 and 18 in adult human corneal endothelium

(2009) Stanislava Merjava et al.   EXPERIMENTAL EYE RESEARCH

Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors

(2009) Banu Ozturk et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Specificity and Accuracy Data for Ligand-binding Assays for Macromolecules Should be Interpreted with Caution

(2008) John W. A. Findlay   AAPS Journal

Optimisation of circulating biomarkers of cell death for routine clinical use

(2008) A. Greystoke et al.   ANNALS OF ONCOLOGY